Home » Psychedelic-assisted therapy for mental health disorders

Psychedelic-assisted therapy for mental health disorders

psychedelic-assisted therapy for mental health disorders

Psychedelic-assisted therapy (PAT) has emerged as an innovative paradigm in mental health, combining psychoactive substances with structured psychotherapy to treat disorders that resist conventional treatment. Unlike traditional psychiatric drugs — which usually require daily doses and act mainly on specific neurotransmitters — psychedelics such as psilocybin, MDMA or LSD induce altered states of consciousness that, in safe clinical settings, can facilitate deep introspection, narrative reconfiguration and neuroplasticity. The applications with the strongest scientific backing are set out below:

1. Treatment-resistant depression

Psilocybin has shown significant efficacy in relieving major depression, especially in cases that have not responded to multiple treatments. A randomised, double-blind, placebo-controlled study published in 2021 in The New England Journal of Medicine showed that a single 25 mg dose of psilocybin reduced depressive symptoms in 70% of participants at three weeks, with sustained effects in 57% at 12 weeks. In 2023 the European Medicines Agency (EMA) granted psilocybin “orphan drug” designation for treatment-resistant depression, speeding up its regulatory pathway. The mechanism is attributed to its agonist action on 5-HT2A receptors, which promotes cortical neuroplasticity and breaks up rigid patterns of negative thinking (“cognitive thawing”).

2. Existential anxiety and generalised anxiety

In patients with terminal illness (such as advanced cancer), psilocybin has produced lasting reductions in existential anxiety and fear of death. A clinical trial at Johns Hopkins University (2016, with a follow-up in 2022) found that 80% of participants maintained a significant clinical improvement in anxiety and mood up to six months after a single session. These effects are linked to experiences of “mysticism” or “unity”, which create a sense of connection and transcendence, reducing rumination and aversion to suffering. Generalised anxiety has also been addressed in preliminary trials, with improvements in tolerance of uncertainty and emotional regulation.

3. Post-traumatic stress disorder (PTSD)

MDMA is the most advanced compound for PTSD. In 2023 the US FDA granted accelerated approval to MDMA-assisted therapy for post-traumatic stress disorder, based on phase 3 trials in which 67% of participants no longer met the diagnostic criteria for PTSD after three sessions, and 71% showed significant clinical improvement. In Europe, Switzerland has allowed compassionate use of MDMA for complex PTSD since the 1990s, and the European MINDSET project (2024–2027) is evaluating its implementation in public health systems. MDMA reduces activity in the amygdala (the fear centre) and increases oxytocin, which makes it easier to process traumatic memories safely during therapy.

4. Addictions

Psychedelic-assisted therapy has shown promising results in treating addiction to alcohol, tobacco and cocaine. A Johns Hopkins University study (2015) reported that 80% of long-term smokers achieved abstinence at six months after two psilocybin sessions, a rate well above that of any available drug treatment. For alcohol, a 2022 trial published in JAMA Psychiatry found that psilocybin reduced heavy drinking days by 90% compared with the control group. The mechanism involves interrupting habit circuits in the default mode network (DMN) and generating intrinsic motivation for change through experiences of “self-transcendence”.


Methodological note

All the treatments described are given in controlled clinical settings, with prior preparation, supervision during the session (by psychiatrists and psychotherapists) and integrative follow-up afterwards. Efficacy depends critically on this therapeutic framework, not on the substance alone.

Keep reading

Funded by the European Union - NextGenerationEURecovery, Transformation and Resilience Plan (Spain)

Funded by the European Union – NextGenerationEU